Endpoints News· @endpts · X·· 29 天前精选AI 评分67
AI 导读
Disc Medicine针对一种使日晒产生疼痛的罕见病药物在III期试验中达到全部终点,该药此前曾被FDA拒绝。原文链接:https://endpoints.news/disc-medicine-reports-sun-allergy-drug-hits-home-run-in-phase-3/
推荐理由
该药曾遭FDA拒绝,此次III期达到全部终点,读者可据此观察其后续申报走向。
正文
After an FDA rejection, Disc Medicine’s drug for a rare disease that makes sun exposure painful hit all endpoints in Phase 3. https://endpoints.news/disc-medicine-reports-sun-allergy-drug-hits-home-run-in-phase-3/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com